Effect of Tirzepatide on Cardiovascular Outcomes.

IF 3 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

American Journal of Cardiovascular Drugs Pub Date : 2025-10-01 DOI:10.1007/s40256-025-00767-4

Jessica Huston, Dontia Orey, Andrew Ashchi, Andrea Ashchi Lachapelle, Ariana Genovese, Jenna Jackson, Ramsey Ashchi, Towfeeq Ashchi, Majdi Ashchi, David Sutton, Wasim Deeb, Rebecca F Goldfaden

引用次数: 0

Abstract

Patients with type 2 diabetes mellitus and obesity have a higher risk of cardiovascular disease and major adverse cardiovascular events. It is important that medication options for these disease states are either cardioprotective or cardioneutral so that the health of the patient is not worsened. Medications in the glucagon-like peptide-1 receptor agonists class decrease cardiovascular risk in those at high or increased risk of cardiovascular events. This review presents and discusses the current clinical and scientific evidence pertaining to tirzepatide, a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor co-agonist.

查看原文本刊更多论文

替西肽对心血管预后的影响。

2型糖尿病合并肥胖患者发生心血管疾病和主要心血管不良事件的风险较高。重要的是，这些疾病状态的药物选择要么是心脏保护，要么是心脏中性，这样患者的健康才不会恶化。胰高血糖素样肽-1受体激动剂类药物可降低心血管事件高风险或高危人群的心血管风险。这篇综述介绍并讨论了目前有关胰高血糖素样肽-1受体/葡萄糖依赖性胰岛素性多肽受体共激动剂替西肽的临床和科学证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Cardiovascular Drugs 医学-心血管系统

CiteScore

6.70

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations. The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.